RO6867461

Phase 1Small molecule

RO6867461 is one of 30 small molecule programs targeting Wet Age-Related Macular Degeneration. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Wet Age-Related Macular DegenerationActive, not recruiting

Active, not recruiting

Competition

Competitive Landscape

43 competitors in Wet Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Macugen

Pfizer

Approved

1 2

Eylea

Regeneron

Phase 3

17 3

Lucentis

Roche

Phase 3

14 4

Avastin

BBio-Thera Solutions

Phase 3

2 5

Retaane

AAlcon Research

Phase 3

1 6

Luye Pharma Conbercept

CChengdu Kanghong Biotech Co., Ltd.

Phase 2

1 7

Inversine

TTargacept Inc.

Phase 2

1 8

Decadron

AAspen Global Incorporated

Phase 2

1 9

EYP-1901

EEyePoint Pharmaceuticals, Inc.

Phase 3

2 10

Lucentis

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Wet Age-Related Macular Degeneration1 trial

A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration

Completed· Roche logo

Roche·Phase 1·NCT01941082·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RO6867461. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RO6867461 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RO6867461. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

RO6867461

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Wet Age-Related Macular Degeneration1 trial

References

Drug Info

Quick Facts

Related News